Zhang W, Zhao YF, Liang FF, Liu XX, Liu JH, Hao JD, Cheng SQ, Wu YF. Role of anlotinib plus albumin paclitaxel regimen in stage IV non-small cell lung cancer and mental state. World J Psychiatry 2025; 15(8): 103735 [DOI: 10.5498/wjp.v15.i8.103735]
Corresponding Author of This Article
Yan-Feng Wu, Assistant Professor, Department of Geriatrics, Zhangjiakou First Hospital in Hebei Province, No. 6 Baisi Lane, Xinhua Front Street, Qiaoxi District, Zhangjiakou 075000, Hebei Province, China. wuyanfeng1128@163.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Wei Zhang, Yun-Fang Zhao, Fei-Fei Liang, Xiao-Xia Liu, Jiang-Hong Liu, Yan-Feng Wu, Department of Geriatrics, Zhangjiakou First Hospital in Hebei Province, Zhangjiakou 075000, Hebei Province, China
Jian-Dong Hao, Department of Respiratory, Zhangjiakou First Hospital in Hebei Province, Zhangjiakou 075000, Hebei Province, China
Shu-Qin Cheng, Department of Psychiatric, Wuhan University of Science and Technology Affiliated Tianyou Hospital, Wuhan 430064, Hubei Province, China
Co-first authors: Wei Zhang and Yun-Fang Zhao.
Author contributions: Zhang W and Zhao YF contributed equally to this study as co-first authors; Zhang W, Zhao YF, and Wu YF designed the research study; Liang FF, Liu XX, Liu JH, and Hao JD performed the primary literature search and data extraction; Zhang W and Zhao YF analyzed the data and wrote the manuscript; Cheng SQ and Wu YF were responsible for revising the manuscript for important intellectual content; all authors read and approved the final version.
Supported by Zhangjiakou Key R&D Program Projects, No. 2021108D.
Institutional review board statement: This study has been reviewed and approved by the Ethics Committee of Zhangjiakou First Hospital (Approval No. 2024128) and adheres to the principles outlined in the Declaration of Helsinki and the Ethical Review Measures for Biomedical Research Involving Human Subjects.
Informed consent statement: The decision to waive informed consent for this study has been approved.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No data available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Feng Wu, Assistant Professor, Department of Geriatrics, Zhangjiakou First Hospital in Hebei Province, No. 6 Baisi Lane, Xinhua Front Street, Qiaoxi District, Zhangjiakou 075000, Hebei Province, China. wuyanfeng1128@163.com
Received: February 26, 2025 Revised: March 21, 2025 Accepted: May 28, 2025 Published online: August 19, 2025 Processing time: 163 Days and 3.5 Hours
Core Tip
Core Tip: In this study, we evaluated the efficacy of anlotinib combined with albumin-paclitaxel in stage IV non-small cell lung cancer (NSCLC). Forty-two patients were split into two groups: one group received albumin-paclitaxel (n = 20), while the other group received anlotinib plus albumin-paclitaxel (n = 22). The study compared clinical outcomes, tumor markers, progression-free survival, overall survival, immune function, quality of life, mental health, and side effects. The combination therapy group showed higher disease remission and control rates, better immune markers and quality of life scores, and lower tumor biomarkers and mental health scores. Adverse reactions were similar in both groups. The combination of anlotinib plus albumin-paclitaxel was effective in treating stage IV NSCLC, reducing depression and anxiety, lowering tumor biomarkers, enhancing immune function, prolonging survival, and improving quality of life.
